CNTB - Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type 2 Inflammation
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.